

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

**(1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE
DIRECTOR; AND**

**(2) CHANGE IN COMPOSITION OF REMUNERATION COMMITTEE,
STRATEGY COMMITTEE AND ENVIRONMENTAL, SOCIAL AND
GOVERNANCE COMMITTEE**

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司* (the “**Company**”) is pleased to announce that Dr. Jue Chen (“**Dr. Chen**”) has been appointed as an independent non-executive Director with effect from August 16, 2023.

The biographical details of Dr. Chen are as follows:

Dr. Chen, aged 53, is a biologist and possesses decades of experience in the biology related sectors. Dr. Chen is currently the William E. Ford Professor at The Rockefeller University, where she has joined since 2014. Dr. Chen has also been serving as an investigator at Howard Hughes Medical Institute since 2008. Prior to such, Dr. Chen joined Purdue University as an assistant professor in 2002, then promoted to an associate professor in 2007 and subsequently served as a professor from 2011 to 2014. Dr. Chen was elected to the National Academy of Sciences in 2019.

Dr. Chen obtained her bachelor of science’s degree in chemistry from Ohio University in 1993 and Ph.D. degree in biochemistry from Harvard University in 1998. She completed her postdoctoral work at Harvard University from 1998 to 1999 and at Baylor College of Medicine from 1999 to 2001.

Dr. Chen does not, at present, nor did she in the past three years, hold any directorship in any public companies the securities of which are listed in Hong Kong or overseas.

Dr. Chen has entered into a director's service agreement with the Company for a term of three years which is terminable by either party with at least 30 days' written notice, and she is subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company in accordance with the articles of association of the Company. Dr. Chen does not have any relationships with any Directors or senior management or substantial shareholders or controlling shareholders of the Company.

As at the date of this announcement, Dr. Chen did not have any interests in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Dr. Chen is entitled to a director's remuneration of HK\$1,200,000 per annum as determined by the Board with reference to Dr. Chen's relevant experience and qualifications, her duties and responsibilities, the prevailing market conditions and the recommendation from the remuneration committee of the Board.

Save as disclosed above, there is no other information which is discloseable nor is/was Dr. Chen involved in any of the matters required to be disclosed pursuant to the requirements under Rules 13.51(2)(h) to (v) of the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and there are no other matters relating to Dr. Chen's appointment that need to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board would like to extend its warmest welcome to Dr. Chen on her new appointment.

CHANGE IN COMPOSITION OF REMUNERATION COMMITTEE, STRATEGY COMMITTEE AND ENVIRONMENTAL, SOCIAL AND GOVERNANCE COMMITTEE

The Board further announces that (i) Dr. Chen has been appointed as a member of the strategy committee of the Board and a member of the environmental, social and governance committee of the Board, both with effect from August 16, 2023; and (ii) Mr. Jackson Peter Tai has been appointed as a member of the remuneration committee of the Board with effect from August 16, 2023.

COMPLIANCE WITH THE LISTING RULES

Reference is made to the announcement of the Company dated May 17, 2023 in relation to the Company being unable to meet the requirement under Rule 13.92 of the Listing Rules, where the Stock Exchange does not consider diversity to be achieved for a single gender board.

Following the above appointment of Dr. Chen with effect from August 16, 2023, the Company has fully complied with the requirement under Rule 13.92 of the Listing Rules.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, August 16, 2023

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive Directors.

* *For identification purpose only*